GETDATA GRAPH DIGITIZER 2.26 KEY FULL

Two researchers independently evaluated article quality and extracted data by screening abstracts and full texts. If more than one article analyzed the same trial, we included only the latest report. Case reports, repeat studies, reviews, and studies lacking full texts were excluded. Studies that met all of the following criteria were included: single-arm studies or randomized controlled trials including CD patients or animal studies studies featuring SC therapy with no restriction imposed on the type of SCs, route of administration, or dose and the inclusion of human CD clinical parameters or animal disease activity index (DAI) scores, histopathological scores (HSs), colon lengths, myeloperoxidase (MPO) and cytokine levels. Two researchers independently screened the titles and abstracts of all retrieved articles. The search string added the keywords focus on CrohnвЂ™s Disease (вЂњCrohnвЂ™s EnteritisвЂќ, вЂњRegional EnteritisвЂќ, вЂњCrohnвЂ™s DiseaseвЂќ, вЂњCrohns DiseaseвЂќ, вЂњInflammatory Bowel Disease 1вЂќ, вЂњEnteritis, GranulomatousвЂќ, вЂњGranulomatous EnteritisвЂќ, вЂњEnteritis, RegionalвЂќ, вЂњIleocolitisвЂќ, вЂњColitis, GranulomatousвЂќ, вЂњGranulomatous ColitisвЂќ, вЂњIleitis, TerminalвЂќ, вЂњIleitis, TerminalвЂќ, вЂњTerminal IleitisвЂќ, вЂњIleitis, RegionalвЂќ and вЂњRegional IleitisвЂќ) and stem cells (вЂњstem cellsвЂќ OR вЂњprogenitor cellsвЂќ, вЂњhematopoietic stem cellsвЂќ, вЂњmesenchymal stem cellsвЂќ, вЂњbone marrow mononuclear cellsвЂќ). We thus systematically reviewed the literature and conducted a meta-analysis on the effectiveness and safety of SC therapy.ДЇive databases (PubMed, Embase, the Web of Science, the Cochrane Library, and Clinical ) were searched from their inception dates to February 2021. Several studies have evaluated the safety and effectiveness of CD stem cell therapy, but the results remain controversial. SCs have been found to inhibit intestinal inflammation, promote long-term intestinal mucosal healing, and significantly improve patient quality of life, making them a valuable alternative CD treatment. HSCs transplantation restored immune tolerance and relieved CD. Randomized controlled experiments have shown that local MSCs injection improved CD-related perianal fistulation. MSCs exhibit low immunogenicity and immunomodulation. Mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) have been shown to counter rheumatoid arthritis, autoimmune hepatitis, and systemic sclerosis. In recent years, developments in stem cell (SC) biology and regenerative medicine have revealed that SCs unexpectedly can be used to treat autoimmuneВ diseases. It is thus critical to enhance CD remission and reduce recurrence. Approximately 25% of CD patients are refractory to such medications and respond to surgery only.

Aggressive вЂњbiological therapiesвЂќ are immunogenic, but their effects fade over time. However, standard anti-inflammatory regimes do not halt disease progression. Corticosteroids (CSs), immunomodulatory agents, and вЂњbiological therapiesвЂќ including anti-TNF-О± antibodies are used to suppress intestinal inflammation. Infections and environmental factors may trigger or exacerbate the disease. The pathogenesis is complex, featuring disturbance of the innate immune system and reduced gastrointestinal barrier protection. The annual incidence of CD ranges from 5.0 to 20.2 per 100,000 person-years, and CD affects more than 1 million people in the USA. Stem cell transplantation is a valuable supplementary therapy for CD.Д¬rohnвЂ™s disease (CD), a form of inflammatory bowel disease (IBD), is an immune system-mediated, chronic systemic condition characterized by gastrointestinal inflammation and dysregulation of the mucosal-associated immune system. CD patients maintained high remission rates for 3вЂ“24В months after transplantation. In clinical trials, stem cell transplantation reduced the CD activity index (SMDвЂ‰в€’вЂ‰2.10, PвЂ‰=вЂ‰0.000), the CD endoscopic index of severity (SMDвЂ‰в€’вЂ‰3.40, PвЂ‰=вЂ‰0.000) and simplified endoscopy score for CD (SMDвЂ‰в€’вЂ‰1.71, PвЂ‰=вЂ‰0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, PвЂ‰=вЂ‰0.305) compared to control values. Rats and mice receiving MSCs exhibited longer colons, lower histopathological scores (mice: SMDвЂ‰в€’вЂ‰4.58, pвЂ‰=вЂ‰0.000 rats: SMDвЂ‰в€’вЂ‰1.41, PвЂ‰=вЂ‰0.000) and lower myeloperoxidase levels (SMDвЂ‰в€’вЂ‰6.22, PвЂ‰=вЂ‰0.000). In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. We evaluated 46 studies including 28 animal works ( nвЂ‰=вЂ‰567) and 18 human trials ( nвЂ‰=вЂ‰360). The SYRCLE risk of bias tool and the MINORS tool were used to assess study quality. The relative outcomes were analyzed with the aid of GetData Graph Digitizer 2.26 and Stata 16.0 software. We explored whether stem cell therapy was effective for animal modelsВ andВ patients with CrohnвЂ™s disease (CD).

Getdata graph digitizer 2.26 key